Knight Therapeutics (TSE:GUD) Price Target Lowered to C$7.50 at Raymond James

Knight Therapeutics (TSE:GUD) had its price objective reduced by Raymond James from C$8.00 to C$7.50 in a note issued to investors on Thursday,BayStreet.CA reports. Raymond James’ price target points to a potential upside of 45.63% from the company’s current price.

A number of other research analysts have also issued reports on GUD. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from C$5.75 to C$6.75 in a report on Tuesday, August 13th.

Knight Therapeutics Stock Performance

GUD stock remained flat at C$5.15 during midday trading on Thursday. The company’s stock had a trading volume of 39,027 shares, compared to its average volume of 69,259. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. The business has a 50-day moving average of C$5.72 and a 200 day moving average of C$5.74. The firm has a market capitalization of C$521.23 million, a PE ratio of -25.75, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 52 week low of C$5.07 and a 52 week high of C$6.23.

Insider Activity

In other news, Director Samira Sakhia purchased 20,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were bought at an average cost of C$5.15 per share, for a total transaction of C$103,000.00. In related news, Director Samira Sakhia acquired 20,000 shares of the business’s stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of C$5.15 per share, for a total transaction of C$103,000.00. Also, insider Sime Armoyan sold 300,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. 45.62% of the stock is currently owned by company insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.